Myopia Management FAQ

Myopia management is the active, evidence-based slowing of the progression of nearsightedness in children — rather than just correcting the blur with stronger glasses every year. The goal is to reduce the axial elongation of the eye and the lifetime risk of conditions like retinal detachment, myopic maculopathy and glaucoma.

Core tools include orthokeratology (ortho-K), low-dose atropine, and myopia-control soft contact lenses, often used in combination. For an ECP, it's a shift in mindset: you stop treating myopia as a refractive inconvenience and start treating it as a progressive condition you can actually intervene in.

The myopia mindset is the shared mentality of the most successful myopia management specialists. After 20 years in this industry, the one thing they have in common isn't a secret protocol — it's a way of thinking: proactive, creative, forward-thinking, and unwilling to accept the status quo of commodity eye care.

They invest in patient care, they treat colleagues as collaborators rather than competitors, and they're genuinely passionate about the work. There is no secret. Passion cannot be taught, but it can be learned — and when you develop your own myopia mindset, the clinical results and the practice growth tend to follow.

There's no single "best" option — the right choice depends on the child's age, prescription, eye health, lifestyle, and what's available in your region.

Orthokeratology reshapes the cornea overnight for clear daytime vision without glasses and reliably reduces axial elongation — a strong fit for active kids and sports. Myopia-control soft lenses (like dual-focus designs) offer similar control with daytime wear. Low-dose atropine is a simple nightly drop that suits younger children or those not ready for contacts. Increasingly the strongest results come from combination therapy — pairing ortho-K with low-dose atropine. The best practitioners match the modality to the patient, not the other way around.

As early as it's warranted. There's strong evidence for myopia control in children roughly 6 to 14 years old, and kids who begin between ages 6 and 8 tend to receive the greatest long-term benefit — earlier intervention means fewer diopters and less axial elongation accumulated over a lifetime.

The practical target population most practices focus on is 8- to 12-year-olds. The key principle: if a child is myopic and progressing, waiting rarely helps. The sooner you intervene, the more vision you can protect.

Yes — ortho-K is considered safe for children when the lens is fit properly and the patient follows wear and care procedures, including good hygiene and keeping tap water away from the lenses.

The biggest controllable risk, microbial keratitis, is rare and is minimized by good fitting, good cleaning habits, and thorough parent and patient education. Decades of pioneer ortho-K practice and a growing body of studies support overnight wear in children. As with any contact lens, safety comes down to proper fit, compliance and follow-up — which is exactly where a well-run myopia management practice earns its trust.

Effective enough to change the trajectory of a child's eyes. On average, orthokeratology reduces axial length elongation by roughly 50% over a two-year period, with low-dose atropine and myopia-control soft lenses showing broadly comparable effects depending on dose and design. Combination therapy can enhance that further.

Tracking axial length — not just refraction — is the gold standard for knowing whether your management is working. That's why axial length measurement has become such a central topic in the specialty.

Combination therapy means using more than one intervention at once — most commonly orthokeratology paired with low-dose atropine. Because the two work through different mechanisms, combining them can produce greater control of axial elongation than either alone, especially in fast progressors or younger, higher-risk children.

Many experienced fitters start with ortho-K, monitor axial length, and add low-dose atropine when a child needs more control. Low-dose atropine as a standalone monotherapy is trickier and less consistently effective than when it's layered onto an optical treatment.

Start with the mindset, then build the systems. Practically: commit to the specialty, get trained, and create a simple one-page FAQ or handout to introduce the topic to families. Retrain your staff — your front desk, techs and a designated "closer" who gets parents excited are as important as your chair-side skills. Rework scheduling and office flow around the longer conversations this requires.

Then lean into education and referrals rather than advertising: when you deliver care this good, your patients and their parents become your best marketing. You don't have to be perfect on day one — there's a learning curve, a lot of art alongside the science, and you'll get better as you go.

Surround yourself with people already doing it well. Conferences like Vision by Design — built specifically for this community — boot camps for new clinicians, and online CE are excellent starting points, alongside resources such as Myopia Profile and Review of Myopia Management.

Just as valuable: talk to colleagues who already run myopia management programs. One of the defining features of this community is that the top specialists love to share what they know — you can learn as much in the hallways as you can from the stage. The podcast itself exists to give you that ongoing motivation, inspiration and education.

Come prepared, create curiosity, and lead with the child's long-term eye health rather than the price. A simple opener works: "Did you know there are several effective options to keep your child's eyes from getting worse so quickly?" Demonstrate progression with loose lenses or a myopia calculator so parents can see the stakes.

Be ready to discuss risks, benefits and alternatives honestly, and send materials home. A practical tip from successful practices: separate the clinical conversation from the money conversation by having a trained staff member handle fees, so you stay focused on care. Above all, be genuinely authentic — be the same person in the exam room that you are at home. That's how you build the trust that gets parents to say yes.

It can be one of the healthiest parts of a modern practice, partly because it reduces dependence on vision plans. Since myopia control is largely not covered by insurance, most practices build cash-pay packages — and parents are often willing to invest when the value is explained well. Billing and coding in this space are still evolving, so you bill the covered medical components appropriately while structuring the management program as a fee-based service.

Done right, myopia management lets you step away from the high-volume, insurance-driven "McDonald's experience" of eye care and build something more rewarding — clinically and financially. (General information, not billing, legal or financial advice; confirm coding and compliance for your jurisdiction.)

As of now there's no FDA-approved commercial low-dose atropine product for myopia control in the U.S., so practitioners rely on compounding pharmacies. The challenge with compounding is consistency: concentration and stability can vary between bottles, which contributes to the up-and-down results sometimes seen in atropine studies. A stable, approved product would solve much of that variability.

This is an active advocacy issue in the community — practitioners watch other countries use tools American children still can't easily access, and many are pushing for approval because, simply put, it changes kids' lives.

If you have the passion for it, absolutely. Myopia management isn't easy — there's a learning curve, trial and error, and creative troubleshooting that only you can do for your own patients. But it's also one of the few areas of eye care where you're genuinely altering a child's lifelong visual future, building deep relationships with families, and differentiating your practice from commodity providers.

It won't be the right fit for every optometrist, and that's okay. But for the ECPs who love it, there's nothing else like it.

No — and that's an honest answer. Not every optometrist or ophthalmologist should be doing myopia management, and there are plenty of other excellent ways to care for patients. The specialty rewards genuine passion and commitment, and forcing it without those rarely works.

But given that the WHO projects roughly half the world's population will be myopic by 2050, the profession needs as many qualified, passionate practitioners addressing this as possible. If the subject matter resonates with you, that's usually a sign it's worth pursuing.